[go: up one dir, main page]

AR020101A1 - Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. - Google Patents

Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.

Info

Publication number
AR020101A1
AR020101A1 ARP990103176A ARP990103176A AR020101A1 AR 020101 A1 AR020101 A1 AR 020101A1 AR P990103176 A ARP990103176 A AR P990103176A AR P990103176 A ARP990103176 A AR P990103176A AR 020101 A1 AR020101 A1 AR 020101A1
Authority
AR
Argentina
Prior art keywords
peptide
group
amino acids
general formula
peptide antagonist
Prior art date
Application number
ARP990103176A
Other languages
English (en)
Original Assignee
Cancerforskingsfonden Af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskingsfonden Af 1989 filed Critical Cancerforskingsfonden Af 1989
Publication of AR020101A1 publication Critical patent/AR020101A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibidores péptidos de la interaccion de union entre el activador de plasminogeno uroquinasa humana (uPA) ysu receptor uPAR. El péptido comprende al menosun fragmento de péptido de la formula general (1) -X1-X2-X3-X4-X5-X6-X7-X8-X9- en donde X1, X5,X6, X7 y X9 son independientemente seleccionados de aminoácidosX1 es el aminoácido N-terminal del fragmento y X9 es el aminoácido C-terminal del fragmento; X2 es seleccionado del grupo que consiste de aminoácidos de laformula general 1, en donde nes un entero en el rango comprendido entre 0 a 3; R1 es seleccionado del grupo que consiste en anillos no aromáticos de cinco,seis, y siete miembros opciionalmente sustituidos; R2 es seleccionado del grupo que consiste de hidrogeno y alquilo C1-4, R1 y R2 junto con el átomo decarbono al cual están unidos forman un anillo ciclopentilo, ciclohexilo, cicloheptilo o decahidronaftalenilo, opcionalmente sustituidos; y aminoácidosN-sustituidos de la formula general 2, en donde n y R1 son como se ha definido anteriormente; X3 y X8 son cada uno independientemente seleccionados del grupoque consiste de aminoácidos que tienen cadenas laterales hidrofobicas que tienen N-sustituyenteshidrofobicos; X4 es seleccionado del grupo que consiste deaminoácidosde la formula general 3, en donde m es un entero en el rango desde 1 a 3, y Y es seleccionado del grupo que consiste de OH, SH, NH2, CONH2, COOH yOPO3H; y aminoácidos N-sustituidos de la formula general 4, en donde m e Y son como se definio anteriormente. Se proveen métodos in vitro e in vivo paraseleccionar antagonistas péptidos que son adecuados para prevenir o contrarrestar actividad proteolítica extracelular localizada de plasmina en un humano.Además, se provee un péptido como se definio anteriormente para utilizar como un medicamento, el uso del péptido para la elaboracion de un medicamento paratratamiento de cáncer, y una composicion farmacéutica que comprende dicho péptido.
ARP990103176A 1998-07-01 1999-06-30 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. AR020101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199800874 1998-07-01

Publications (1)

Publication Number Publication Date
AR020101A1 true AR020101A1 (es) 2002-04-10

Family

ID=8098519

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103176A AR020101A1 (es) 1998-07-01 1999-06-30 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.

Country Status (4)

Country Link
US (1) US7026282B1 (es)
AR (1) AR020101A1 (es)
AU (1) AU4768899A (es)
WO (1) WO2000001802A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202212A2 (hu) * 2002-07-10 2004-04-28 Comgenex Rt. Új kombinatorikus fehérjemarker molekulakönyvtárak, eljárás azok előállítására és alkalmazására
RU2394837C2 (ru) * 2004-09-29 2010-07-20 Джи-И Хелткер АС Контрастный агент, нацеленный на рецептор урокиназного активатора плазминогена
US20070244046A1 (en) * 2006-03-29 2007-10-18 Margarita Gutova Identification and characterization of cancer stem cells and methods of use
US7902327B2 (en) * 2007-05-22 2011-03-08 New York University School Of Medicine Dendrimeric peptides, pharmaceutical compositions and methods of using the same
CN104768573B (zh) 2012-05-08 2017-08-29 Trt创新有限责任公司 用于位点特异性uPAR靶向的177‑Lu标记肽
EP3590542B1 (en) 2012-12-03 2024-01-03 Curasight A/S Positron emitting radionuclide labeled peptides for human upar pet imaging
DK3193945T3 (da) 2014-09-17 2020-11-16 Fluoguide As Upar-målrettende peptid til anvendelse ved peroperativ optisk billeddannelse af invasiv cancer
CN108937848B (zh) * 2017-05-23 2022-12-09 赫玛超生物科技(上海)有限公司 用于进行白血病诊疗的系统
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
WO2024153756A1 (en) 2023-01-18 2024-07-25 Curasight A/S Radionuclide labelled peptide conjugate for site-specific upar-targeting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
EP0842281A1 (en) * 1995-07-31 1998-05-20 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
JP2001519647A (ja) 1995-12-28 2001-10-23 カイロン コーポレイション 標的細胞中へのウイルスおよび粒子の取り込みおよびインターナリゼーションのためのレセプター特異的キメラウイルス表面ポリペプチド
JP4088344B2 (ja) * 1996-03-28 2008-05-21 カイロン コーポレイション ウロキナーゼレセプターのペプチドリガンド
WO1997037020A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides

Also Published As

Publication number Publication date
WO2000001802A2 (en) 2000-01-13
WO2000001802A3 (en) 2000-04-27
AU4768899A (en) 2000-01-24
US7026282B1 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
MC2144A1 (fr) Peptides therapeutiques
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
DK1144454T3 (da) Modificerede peptider som terapeutiske midler
TR200103337T2 (tr) Protez inhibit”rleri olarak yeni bileçikler ve bileçimler
Takagi et al. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity
DK0679092T3 (da) Cytokindæmpende midler
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
IL156843A0 (en) Combined use of factor vii polypeptides and factor viii polypeptides
AR020101A1 (es) Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
SE0102440D0 (sv) New compound
ATE364315T1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US6191103B1 (en) Methods for enhancing thrombolysis in a mammal
Koizumi et al. Structure–activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
AU3739500A (en) Protease resistant flint analogs
ATE540968T1 (de) Alpha-fetoproteinpeptide und deren verwendungen
Park et al. Selective inhibition of human inducible nitric oxide synthase by S‐alkyl‐L‐isothiocitrulline‐containing dipeptides
HU208028B (en) Process for producing peptides of bradichinine-antagonistic activity and pharmaceutical compositions containing them
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
AR023192A1 (es) Analogos de las flint resistentes a proteasas
ECSP003405A (es) Analogos de las flint resistentes a proteasas (caso x- 13161)